Office Action Predictor
Last updated: April 15, 2026
Application No. 18/199,527

HYDROXYALKYLALKYL CELLULOSE FOR TABLETING AND SOLID PREPARATION COMPRISING THE SAME

Non-Final OA §103
Filed
May 19, 2023
Examiner
MERCIER, MELISSA S
Art Unit
1615
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Shin-Etsu Chemical Co., LTD.
OA Round
2 (Non-Final)
72%
Grant Probability
Favorable
2-3
OA Rounds
2y 10m
To Grant
76%
With Interview

Examiner Intelligence

Grants 72% — above average
72%
Career Allow Rate
852 granted / 1181 resolved
+12.1% vs TC avg
Minimal +3% lift
Without
With
+3.4%
Interview Lift
resolved cases with interview
Typical timeline
2y 10m
Avg Prosecution
50 currently pending
Career history
1231
Total Applications
across all art units

Statute-Specific Performance

§101
1.1%
-38.9% vs TC avg
§103
41.2%
+1.2% vs TC avg
§102
17.1%
-22.9% vs TC avg
§112
25.3%
-14.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1181 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Information Disclosure Statement Receipt of the Information Disclosure Statements filed on May 23, 2023 and November 20, 2023 is acknowledged. Signed copies are attached to this office action. The listing of references in the specification is not a proper information disclosure statement. 37 CFR 1.98(b) requires a list of all patents, publications, or other information submitted for consideration by the Office, and MPEP § 609.04(a) states, "the list may not be incorporated into the specification but must be submitted in a separate paper." Therefore, unless the references have been cited by the examiner on form PTO-892, they have not been considered. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 1-7 are rejected under 35 U.S.C. 103 as being unpatentable over Koyanagi et al. (US 3,852,421) in view of JP200502740 (hereinafter referred to as JP740). Koyanagi discloses an excipient comprising hydroxylalkylalkyl cellulose used in the preparation of compressed, hard, readily disintegrable tablets (abstract). The cellulose ethers are prepared by the well-known conventional method which consists of: (i) dipping pulp in a 10-30% aqueous solution of caustic soda and pressing it into alkali cellulose, (ii) charging the alkali cellulose together with alkylene oxide (etherifying agent) into a reactor and reacting same therein at 20-50.degree.C and under pressure, for 2-5 hours, (iii) thereafter neutralizing by washing the hydroxyalkyl cellulose or hydroxyalkyl alkylcellulose thus prepared with alkali, (iv) then further washing the neutralized hydroxyalkyl cellulose or hydroxyalkyl alkylcellulose with water and pulverizing it, or cooling to 0.degree.-10.degree.C the neutralized hydroxyalkyl cellulose or hydroxyalkyl alkylcellulose containing from 30 to 70% of water, drying it, then pulverizing it. In order to make its particle size and apparent density as given above, the pulverized cellulose ether may be further ground by means of a device such as an atomizer. Hydroxyalkyl cellulose or hydroxyalkylalkyl cellulose (first hydroxyalkylalkyl cellulose) powder is thus prepared (column 2, lines 50-68). Regarding claim 3, as noted above, the neutralized pulverized cellulose ether (first hydroxyalkylalkyl cellulose) is washed, dried, and pulverized. Regarding claim 7, the cellulose ether may be shaped into tablets via dry and direct compression (column 2, lines 45-46). Lowey does not disclose subjecting the ground first hydroxyalkylalkyl cellulose to hydrolysis in the presence of an acid catalyst or oxidative degradation in the presence of an oxidant for depolymerization to obtain a second hydroxyalkylalkyl cellulose. JP470 discloses a method of depolymerizing cellulose ether by acid/oxidative degradation. Ground and dried cellulose ether is first gassed with a gaseous acid or sprayed with an acid solution and contacted with an oxidizing agent or with an oxidizing agent solution (abstract). Regarding claim 2, Example 1 discloses the depolymerized cellulose (second hydroxyalkylalkyl cellulose) is disclosed to be pulverized (grinding) Regarding claims 4 and 6, JP740 discloses the degradation of the cellulose results in the production of low viscosity cellulose ethers from higher viscosity cellulose ethers. Based on the disclosure of Lowey the viscosities of the several grades of hydroxypropylmethylcellulose, as calculated based on the viscosity of a 2% aqueous solution at 20 ˚C, range from 5-100,000cps. Typically, the higher viscosity grade materials dissolve more slowly and can be used in lesser amounts than comparable materials having lesser viscosities (Lowey, column 2, lines 5-11). Therefore, the skilled artisan would be motivated to reduce the viscosity of the ether for use in pharmaceutical formulations. Regarding claim 5, the acid catalyst is disclosed to include hydrochloric acid, sulfuric acid, nitric acid, and phosphoric acid (paragraph 0032). It would have been obvious to one of ordinary skill in the art prior to the effective filing date of the invention to have further processed the cellulose of Koyanagi according to the method of JP740 in order produce very low viscosity cellulose ether having a high whiteness (paragraph 0023). Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to MELISSA S MERCIER whose telephone number is (571)272-9039. The examiner can normally be reached M-F 6:30 am to 4 pm EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Robert A Wax can be reached at 571-272-0623. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MELISSA S MERCIER/ Primary Examiner, Art Unit 1615
Read full office action

Prosecution Timeline

May 19, 2023
Application Filed
Oct 03, 2025
Non-Final Rejection — §103
Apr 02, 2026
Response Filed
Apr 14, 2026
Final Rejection — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12576064
UROLITHIN GUMMY (PECTIN) FORMULATIONS
2y 5m to grant Granted Mar 17, 2026
Patent 12569454
NUCLEOPHILIC CHEMICALS USEFUL IN THE TREATMENT OF CISPLATIN-INDUCED SENSORY NEUROPATHY AND OTOTOXICITY
2y 5m to grant Granted Mar 10, 2026
Patent 12569445
PARTICLES COMPRISING A THERAPEUTIC OR DIAGNOSTIC AGENT AND SUSPENSIONS AND METHODS OF USE THEREOF
2y 5m to grant Granted Mar 10, 2026
Patent 12564553
SUSPENSION CONTAINING HETEROCYCLIDENE ACETAMIDE DERIVATIVE
2y 5m to grant Granted Mar 03, 2026
Patent 12558363
COMPOSITIONS FOR CLINICAL COMPLICATIONS ASSOCIATED TO DEVICES IMPLANTED IN THE URINARY TRACT
2y 5m to grant Granted Feb 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

2-3
Expected OA Rounds
72%
Grant Probability
76%
With Interview (+3.4%)
2y 10m
Median Time to Grant
Moderate
PTA Risk
Based on 1181 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in for Full Analysis

Enter your email to receive a magic link. No password needed.

Free tier: 3 strategy analyses per month